No information provided.
Sodium retention
Fluid retention
Congestive heart failure in susceptible patients
Potassium loss
Hypokalemic alkalosis
Hypertension
Muscle weakness
Steroid myopathy
Loss of muscle mass
Osteoporosis
Tendon rupture, particularly of the Achilles tendon
Vertebral compression fractures
Aseptic necrosis of femoral and humeral heads
Pathologic fracture of long bones
Peptic ulcer with possible perforation and hemorrhage
Pancreatitis
Abdominal distention
Ulcerative esophagitis
Increases in alanine transaminase (ALT, SGPT), aspartate
transaminase (AST, SGOT) and alkaline phosphatase have been observed following
corticosteroid treatment. These changes are usually small, not associated with
any clinical syndrome and are reversible upon discontinuation.
Impaired wound healing
Thin fragile skin
Petechiae and ecchymoses
Facial erythema
Increased sweating
May suppress reactions to skin tests
Increased intracranial pressure with papilledema
(pseudotumor cerebri) usually after treatment
Convulsions
Vertigo
Headache
Development of Cushingoid state
Suppression of growth in children
Secondary adrenocortical and pituitary unresponsiveness,
particularly in times of stress, as in trauma, surgery or illness
Menstrual irregularities
Decreased carbohydrate tolerance
Manifestations of latent diabetes mellitus
Increased requirements for insulin or oral hypoglycemic
agents in diabetics
Posterior subcapsular cataracts
Increased intraocular pressure
Glaucoma
Exophthalmos
Negative nitrogen balance due to protein catabolism
Sodium retention
Fluid retention
Congestive heart failure in susceptible patients
Potassium loss
Hypokalemic alkalosis
Hypertension
Muscle weakness
Steroid myopathy
Loss of muscle mass
Osteoporosis
Tendon rupture, particularly of the Achilles tendon
Vertebral compression fractures
Aseptic necrosis of femoral and humeral heads
Pathologic fracture of long bones
Peptic ulcer with possible perforation and hemorrhage
Pancreatitis
Abdominal distention
Ulcerative esophagitis
Increases in alanine transaminase (ALT, SGPT), aspartate
transaminase (AST, SGOT) and alkaline phosphatase have been observed following
corticosteroid treatment. These changes are usually small, not associated with
any clinical syndrome and are reversible upon discontinuation.
Impaired wound healing
Thin fragile skin
Petechiae and ecchymoses
Facial erythema
Increased sweating
May suppress reactions to skin tests
Increased intracranial pressure with papilledema
(pseudotumor cerebri) usually after treatment
Convulsions
Vertigo
Headache
Development of Cushingoid state
Suppression of growth in children
Secondary adrenocortical and pituitary unresponsiveness,
particularly in times of stress, as in trauma, surgery or illness
Menstrual irregularities
Decreased carbohydrate tolerance
Manifestations of latent diabetes mellitus
Increased requirements for insulin or oral hypoglycemic
agents in diabetics
Posterior subcapsular cataracts
Increased intraocular pressure
Glaucoma
Exophthalmos
Negative nitrogen balance due to protein catabolism
DRUG INTERACTIONSThe pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
